Combination drug loaded lipid-based nanocarriers as treatment entity for battling glioblastoma multiforme

• Published in: Journal of drug delivery science and technology 2023-09, Vol.87, p.104800, Article 104800
• Main Authors: Qamar, Zufika, Sartaj, Ali, Iqubal, Mohammad Kashif, Qizilbash, Farheen Fatima, Sabir, Suhaira, Ali, Javed, Ali, Asgar, Baboota, Sanjula
• Format: Article
• Language: English
• Subjects: Drug combination; Glioblastoma multiforme; Liposomes; Nanoemulsions; Nanostructured lipid carriers; Solid lipid nanoparticles
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2023.104800

Glioblastoma multiforme (GBM) is the most lethal form of brain cancer pigeonholed by a high rate of reoccurrence and poor diagnosis. Among all treatment strategies available, chemotherapy is considered the most common treatment entity at a clinical level. Combination chemotherapy is believed to be a mainstay for the management of GBM compared to monotherapy. As it augments the efficiency of the drugs and targets the tumor site either in an additive or synergistic way. But, due to various limitations of drugs, explicitly poor solubility, low permeability, and inability to cross the blood-brain barrier and blood-brain tumor barrier. Seeing these, there comes a need to load them in lipid-based nanocarriers. As it would help in the targeted delivery of drugs, thereby improving the pharmacokinetic profile of drugs in blood and at the tumor site. So, this article delivers a brief review of using various lipid-based nanocarriers loaded with drug combinations against GBM. [Display omitted] •Glioblastoma multiforme (GBM) is the most lethal form of brain cancer.•GBM is associated with a high rate of reoccurrence and poor diagnosis.•Targeting multiple pathways via combinatorial approach.•Lipid-based nanocarriers that are loaded with drug combination to combat GBM.•Augmenting the targeting specificity of nanocarriers through conjugation with receptor-specific modes.